

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/251620 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/4035 (2006.01)
A61K 9/20 (2006.01) A61K 9/28 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2022/031325

(22) International Filing Date:

27 May 2022 (27.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/194,247 28 May 2021 (28.05.2021) US

Published:

— with international search report (Art. 21(3))

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: BENNETTE, Nathan; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). CALDWELL, William Brett; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). HOSTETLER, Christi; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). INGRAM, Kazden; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). KING, Dory; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). KYBURZ, Kyle; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). VILES, Alison; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: BARNETT, Derek W. et al.; Marshall, Gerstein & Borun LLP, 233 S Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: FORMULATIONS OF APREMILAST

(57) Abstract: Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

WO 2022/251620 A1